AIM AIM ImmunoTech Inc.

0.93
-0.08  -8%
Previous Close 1.01
Open 1
Price To Book 0.59
Market Cap 7,686,313
Shares 8,263,964
Volume 839,006
Short Ratio 0.19
Av. Daily Volume 1,202,232
Stock charts supplied by TradingView

NewsSee all news

  1. AIM ImmunoTech to Present at the Investor Summit in Philadelphia

    OCALA, FL / ACCESSWIRE / December 11, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announced that it

  2. AIM ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020

    OCALA, FL / ACCESSWIRE / December 4, 2019 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases -

  3. CORRECTION: AIM ImmunoTech Provides Business Update for the Third Quarter of 2019

    This press release replaces the press release issued 11/15/2019 at 6:30 a.m., which included an incorrect date. The company had cash, cash equivalents and marketable securities of $1,825,000 as of December 31, 2018, not

  4. AIM ImmunoTech Provides Business Update for the Third Quarter of 2019

    OCALA, FL / ACCESSWIRE / November 15, 2019 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases -

  5. AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified

    Well Capitalized to Complete Current Ampligen Clinical Trials Following $10M in Capital Raises Plus $15M Recently Awarded by DOD to Roswell Park and Moffitt for Ampligen-Related Breast Cancer TrialsOCALA, FL / ACCESSWIRE

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL February 4, 2013.
Ampligen
CFS
Phase 1 data due around 2Q 2020.
Ampligen, Intron A, celecoxib and pembrolizumab
Triple-Negative Breast Cancer
Phase 2 interim data due around 2Q 2020.
Ampligen, Intron A, and celecoxib
Colorectal cancer
Phase 2 interim data due around 4Q 2020.
Ampligen, cisplatin and pembrolizumab
Ovarian cancer
Phase 2 trial to commence enrolment in 4Q 2019.
Ampligen, Intron A
Prostate Cancer
Phase 1 interim data to be presented 1Q 2020.
Ampligen plus Intron A
Ovarian cancer

Latest News

  1. AIM ImmunoTech to Present at the Investor Summit in Philadelphia

    OCALA, FL / ACCESSWIRE / December 11, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announced that it

  2. AIM ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020

    OCALA, FL / ACCESSWIRE / December 4, 2019 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases -

  3. CORRECTION: AIM ImmunoTech Provides Business Update for the Third Quarter of 2019

    This press release replaces the press release issued 11/15/2019 at 6:30 a.m., which included an incorrect date. The company had cash, cash equivalents and marketable securities of $1,825,000 as of December 31, 2018, not

  4. AIM ImmunoTech Provides Business Update for the Third Quarter of 2019

    OCALA, FL / ACCESSWIRE / November 15, 2019 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases -

  5. AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified

    Well Capitalized to Complete Current Ampligen Clinical Trials Following $10M in Capital Raises Plus $15M Recently Awarded by DOD to Roswell Park and Moffitt for Ampligen-Related Breast Cancer TrialsOCALA, FL / ACCESSWIRE

  6. AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering

    OCALA, FL / ACCESSWIRE / September 25, 2019 / AIM ImmunoTech, Inc. (NYSE:AIM) (the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of

  7. AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center

    New Ampligen-Related Strategy for Treating Advanced Breast Cancer Helps Earn 'Breakthrough Award'OCALA, FL / ACCESSWIRE / September 24, 2019 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the

  8. AIM ImmunoTech's Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome

    Important Milestone to Commercial Launch in Argentina AchievedOCALA, FL / ACCESSWIRE / September 24, 2019 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to

  9. AIM ImmunoTech Inc. Announces the U.S. Department of Defense's Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer

    New Ampligen-Related Strategy for Treating Advanced Breast Cancer Earns 'Breakthrough Award'OCALA, FL / ACCESSWIRE / September 19, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused

  10. AIM ImmunoTech Names Ellen Lintal as New Chief Financial Officer

    OCALA, FL / ACCESSWIRE / September 16, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency

  11. AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City

    OCALA, FL / ACCESSWIRE / September 13, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency

  12. AIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center

    OCALA, FL / ACCESSWIRE / September 10, 2019 / AIM ImmunoTech Inc., (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency